首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Elucidation of the pharmacophore of echinocystic acid, a new lead for blocking HCV entry
【24h】

Elucidation of the pharmacophore of echinocystic acid, a new lead for blocking HCV entry

机译:阐明囊藻酸的药效基团,一种阻止HCV进入的新途径

获取原文
获取原文并翻译 | 示例
       

摘要

To elucidate the pharmacophore of echinocystic acid (EA), an oleanane-type triterpene displaying substantial inhibitory activity on HCV entry, two microbial strains, Rhizopus chinensis CICC 3043 and Alternaria alternata AS 3.4578, were utilized to modify the chemical structure of EA. Eight new metabolites with regio- and stereo-selective introduction of hydroxyl and lactone groups at various inert carbon positions were obtained. The anti-HCV entry activity of the metabolites 2-13, along with their parental compound EA and other analogs 14-15, were evaluated. Most of the metabolites showed no improvement but detrimental effect on potency except compound 5 and 6, which showed similar and even a litter higher anti-HCV entry activity than that of EA. The results demonstrated that ring A, B, C and the left side of ring E of EA are highly conserved, while ring D and the right side of ring E of EA are flexible. Introduction of a hydroxyl group at C-16 enhanced the triterpene potency. Further analysis indicated that the hemolytic effect of EA disappeared upon such modifications.
机译:为了阐明棘孢囊酸(EA)的药效基团,是一种对HCV进入显示出实质性抑制活性的齐墩果烷型三萜,使用了两种微生物菌株,即中华根霉CICC 3043和链格孢变种AS 3.4578,来修饰EA的化学结构。获得了八种新的代谢物,它们在不同的惰性碳位置上通过区域和立体选择性引入了羟基和内酯基。评估了代谢物2-13及其亲代化合物EA和其他类似物14-15的抗HCV进入活性。除化合物5和6以外,大多数代谢产物均未显示出改善效果,但对效能有不利影响,与EA相比,其抗HCV进入活性相似,甚至更高。结果表明,EA的环A,B,C和E的左侧是高度保守的,而EA的环D和E的右侧则是柔性的。在C-16处引入羟基增强了三萜的效力。进一步的分析表明,EA的溶血作用在这种修饰后就消失了。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号